Regxia
Regxia is a Canadian scientific and regulatory consulting firm serving small and mid-sized pharmaceutical and biotech companies in Canada and the US with regulatory strategy, eCTD submissions, XML Product Monograph preparation, quality assurance, and pharmacovigilance services.
- Company typePrivate
- Founded2007
- HeadquartersVaughan, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Regxia does
Regxia Inc. is a privately held Canadian scientific and regulatory consulting firm founded in 2007 by Betty Cory and Lori de Munnik, headquartered in Vaughan, Ontario. The firm serves small and mid-sized pharmaceutical and biotechnology companies in Canada and the United States, providing end-to-end regulatory support across the product lifecycle — from pre-clinical development through clinical phases, CMC, submission, and post-marketing pharmacovigilance. Regxia's service portfolio is organized into three pillars: regulatory consulting (dossier compilation, scientific and strategic advice, CMC, and clinical regulatory support), ePublishing (eCTD compilation and lifecycle management, and XML Product Monograph preparation using a proprietary validated platform with over 15,000 e-submissions completed to date), and quality services (QA system development, Drug Establishment Licensing, GMP inspection management, pharmacovigilance system compliance, and safety reporting).
The company operates a platform-plus-services model, with two notable proprietary technology assets: a validated eCTD electronic submission system and a proprietary digital platform that transforms Word-based Product Monographs into Health Canada-conformant validated XML submissions, including viewer-friendly HTML output. Regxia also maintains a technology integration partnership with Court Square Group to deliver fit-for-purpose pharmacovigilance solutions for smaller pharma clients that lack enterprise-scale PV infrastructure. The firm has participated in Health Canada's XML PM pilot program and positions itself as offering Health Canada and FDA dual-jurisdiction expertise that larger Big Pharma-focused consultancies do not target.
Regxia generates revenue through customized professional services engagements — project-based or retainer — sold directly to clients in the Canadian and US pharma and biotech markets. Pricing is quote-based and not publicly disclosed. The firm markets primarily through content (the 'Regxia Review' blog), organic social media (LinkedIn, Facebook, Twitter), and industry events such as the CAPRA Pharmaceutical Symposium, and is led by a founder-owned management team of 11-50 employees with no external capital raised since founding.
Regxia firmographics
Firmographics- Name
- Regxia
- Legal name
- Regxia Inc.
- Website
- https://regxia.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Regxia is a Canadian scientific and regulatory consulting firm serving small and mid-sized pharmaceutical and biotech companies in Canada and the US with regulatory strategy, eCTD submissions, XML Product Monograph preparation, quality assurance, and pharmacovigilance services.
- Ownership category
- akta.pro rank
Regxia industry classification
Industry- Product category
- Pharmaceutical Regulatory Consulting
- NAICS
- Scientific Research and Development Services (5417), Professional, Scientific, and Technical Services (54)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Regulatory Compliance Management (RegTech) (BPAEAPAB)
Keywords
Where Regxia is headquartered
LocationHeadquarters
- HQ city
- Vaughan
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Regxia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Regulatory Consulting Services: Regxia provides scientific and regulatory consulting services including dossier compilation, scientific advice, CMC support, and clinical regulatory support to pharmaceutical and biotech companies. Services are customized to each client's needs.
- ePublishing Services: Electronic submission publishing services including eCTD compilation and lifecycle management, XML Product Monograph preparation and validation, and adaptation of submissions for new markets.
- Quality and Pharmacovigilance Services: Quality assurance system support, pharmacovigilance system management, periodic safety reports (PSUR, PBRER, PADER), promotional material reviews, and GVP self-inspections for small to mid-sized pharma companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Regxia product offering
Product offeringCore offering
Regxia is a scientific and regulatory consulting firm that delivers customized regulatory affairs, ePublishing, quality assurance, and pharmacovigilance services to small and mid-sized pharmaceutical and biotech companies seeking Health Canada and FDA market access. Its core offerings include dossier compilation and management, scientific and strategic consulting, CMC and clinical regulatory support, validated eCTD submission publishing, proprietary XML Product Monograph preparation, full quality assurance system development, and ongoing pharmacovigilance and safety reporting. Services are delivered by an in-house team of regulatory experts through direct consulting engagements.
Product overview
Regxia is a scientific and regulatory consulting firm serving pharmaceutical and biotech industries with expertise in Canadian and US regulatory affairs. The company operates as a platform-plus-services model, offering core ePublishing services (eCTD submissions and XML Product Monographs), regulatory services (dossier compilation, scientific consulting, CMC, and clinical support), and quality services (quality assurance systems and pharmacovigilance). All services are delivered through their team of regulatory experts and leverage proprietary validated systems for electronic submissions. With over 15,000 e-submissions completed to date, the company provides end-to-end regulatory support from pre-clinical development through post-approval lifecycle management.
Differentiator
Problem solved
Functional benefit
Products and services
- eCTD Submission Services Electronic Common Technical Document (eCTD) submission services for regulatory submissions to Health Canada and the FDA, including initial builds of CTAs/INDs and NDSs/NDAs, lifecycle management, and takeover of existing e-dossiers, supported by a validated publishing system with over 15,000 submissions completed to date.
- XML Product Monograph Services Structured XML Product Monograph preparation, validation, and submission services using a proprietary digital platform that conforms to Health Canada's controlled vocabulary and structural requirements, transforming Word documents into validated XML PM submissions that clients can use without XML coding expertise.
- Dossier Compilation and Management Comprehensive regulatory submission management including eCTD compilation, adaptation for new markets, and review of CMC, nonclinical and clinical dossiers for pharmaceutical and biotech sponsors.
- Scientific and Strategic Consulting Strategic regulatory advice including gap analysis of dossiers, agency meeting support, and literature reviews for SRTD or 505(b)(2) applications, provided to pharmaceutical and biotech sponsors.
- Chemistry, Manufacturing, and Controls (CMC) Regulatory CMC consulting leveraging trusted relationships with agency evaluators to strategically position dossiers for lifecycle approval, supported by specific expertise in Chemistry and Manufacturing development and documentation for pharmaceuticals and biotech products.
- Clinical Regulatory Support Strategic clinical regulatory advice throughout the drug development process with integration of nonclinical, CMC, and clinical programs for pharmaceutical and biotech sponsors.
- Quality Assurance System Canadian Quality Services including SOP development, Drug Establishment Licensing coordination, Health Canada GMP inspection management, and ongoing compliance support, designed as an all-inclusive QA solution for small to mid-sized companies.
- Pharmacovigilance and Safety Reporting Compliant pharmacovigilance system with SOPs, templates and timelines; periodic safety reports (PSUR, PBRER, PADER); promotional materials reviews; and GVP self-inspections for small to mid-sized pharma companies.
Quantifiable outcome
- Over 15,000 e-submissions completed successfully using validated publishing systems
- +1 more outcomes
Companies that use Regxia
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Regxia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Regxia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Court Square GroupcoreRegxia partners with Court Square Group to provide integrated pharmacovigilance solutions for small and mid-sized pharma companies. The partnership combines Regxia's regulatory expertise with Court Square Group's PV technology platform, offering fit-for-purpose, affordable, and compliant pharmacovigilance systems that meet Health Canada and FDA requirements without requiring enterprise-level infrastructure.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Regxia competitors and assessment
Company assessmentEmerging players
- Veeva Systems: Veeva provides cloud-based regulatory information management (Vault RIM) and content management platforms to life sciences companies. Not a direct consulting competitor, but its technology platforms increasingly automate submission management work that Regxia performs manually, representing a structural competitive threat.
Direct peers
- PharmaLex: PharmaLex is a regulatory and pharmacovigilance consulting firm serving pharma and biotech clients. Directly comparable to Regxia in providing dossier compilation, submission support, and quality compliance services, though with broader global geographic reach.
- ProPharma Group: ProPharma Group provides regulatory affairs, quality compliance, and pharmacovigilance consulting services to pharmaceutical, biotech, and medical device companies. Highly comparable to Regxia in its outsourced regulatory and quality services model targeting small and mid-sized life sciences companies.
- Voisin Consulting Life Sciences: Voisin Consulting provides regulatory affairs, clinical development, and quality compliance services to pharma and biotech. Comparable to Regxia as a specialized regulatory and quality consulting firm serving life sciences clients across multiple geographies.
- NAMSA: NAMSA provides regulatory, quality, and clinical research services to medical device and biologics manufacturers. Comparable to Regxia as an outsourced regulatory and quality consulting firm serving small and mid-sized life sciences companies.
- Alacrita: Alacrita is a life sciences consulting firm offering regulatory strategy, clinical development, and commercial advisory to pharma and biotech. Comparable to Regxia in its specialized regulatory consulting model for small and mid-sized life sciences companies.
Broad incumbents
- Parexel International: Parexel is a major global CRO with comprehensive regulatory affairs and submission services. Overlaps with Regxia's regulatory consulting offerings, but its full-service CRO model targets larger enterprise clients.
- ICON plc: ICON plc is a global CRO providing regulatory, clinical, and laboratory services to pharma and biotech. Competes with Regxia in the regulatory consulting space, though positioned as a broad incumbent serving larger enterprise clients.
- IQVIA: IQVIA is a large global CRO and life sciences services company with extensive regulatory consulting capabilities. Comparable as a competitor for regulatory services, though its scale and full-service CRO model position it as a broad incumbent rather than a direct specialist competitor.
Regional players
- PharmEng Technology: PharmEng Technology is a Canadian pharmaceutical consulting firm providing regulatory affairs, validation, and quality services. Comparable to Regxia in scope and Canadian market focus, though operates primarily in GMP validation and engineering services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Regxia social profiles
Digital presenceRegxia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Regxia leadership team
Management profileNumber of profiles
Profiles6 records
Regxia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Regxia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Regxia
What does Regxia do?
Regxia is a scientific and regulatory consulting firm that delivers customized regulatory affairs, ePublishing, quality assurance, and pharmacovigilance services to small and mid-sized pharmaceutical and biotech companies seeking Health Canada and FDA market access. Its core offerings include dossier compilation and management, scientific and strategic consulting, CMC and clinical regulatory support, validated eCTD submission publishing, proprietary XML Product Monograph preparation, full quality assurance system development, and ongoing pharmacovigilance and safety reporting. Services are delivered by an in-house team of regulatory experts through direct consulting engagements.
Is Regxia a public or private company?
Regxia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Regxia founded?
Regxia was founded in 2007. It employs 11 to 50 people.
Where is Regxia based?
Regxia is headquartered in Vaughan, Canada, in the North America region.
How does Regxia make money?
Three revenue lines are on record. Regulatory Consulting Services are the primary driver. The others are ePublishing Services and quality and Pharmacovigilance Services.
Who are Regxia's main competitors?
Veeva Systems is listed as an emerging player. Direct peers are PharmaLex, ProPharma Group, Voisin Consulting Life Sciences, NAMSA and Alacrita. Broad incumbents are Parexel International, ICON plc and IQVIA. PharmEng Technology is listed as a regional player.
Does Regxia have an API?
No public API is recorded for Regxia.
What industry is Regxia in?
Regxia's product category is Pharmaceutical Regulatory Consulting. Its primary akta.pro industry code is BPAEAPAB, Regulatory Compliance Management (RegTech). Its NAICS code is 5417 and its SIC code is 8731.